The East Asian Paradox: An Updated Position Statement on the Challenges to the Current Antithrombotic Strategy in Patients with Cardiovascular Disease

Hyun Kuk Kim, Udaya S. Tantry, Sidney C. Smith, Myung Ho Jeong, Seung Jung Park, Moo Hyun Kim, Do Sun Lim, Eun Seok Shin, Duk Woo Park, Yong Huo, Shao Liang Chen, Zheng Bo, Shinya Goto, Takeshi Kimura, Satoshi Yasuda, Wen Jone Chen, Mark Chan, Daniel Aradi, Tobias Geisler, Diana A. GorogDirk Sibbing, Gregory Y.H. Lip, Dominick J. Angiolillo, Paul A. Gurbel, Young Hoon Jeong

Research output: Contribution to journalReview articlepeer-review

3 Citations (Scopus)

Abstract

East Asian patients have reduced anti-ischemic benefits and increased bleeding risk during antithrombotic therapies compared with Caucasian patients. As potent P2Y 12 receptor inhibitors (e.g., ticagrelor and prasugrel) and direct oral anticoagulants are commonly used in current daily practice, the unique risk-benefit trade-off in East Asians has been a topic of emerging interest. In this article, we propose updated evidence and future directions of antithrombotic treatment in East Asian patients.

Original languageEnglish
Pages (from-to)422-432
Number of pages11
JournalThrombosis and Haemostasis
Volume121
Issue number4
DOIs
Publication statusPublished - 2021 Apr 1

Keywords

  • antiplatelet therapy
  • bleeding risk
  • direct oral anticoagulants
  • ischemic risk
  • race

ASJC Scopus subject areas

  • Hematology

Fingerprint Dive into the research topics of 'The East Asian Paradox: An Updated Position Statement on the Challenges to the Current Antithrombotic Strategy in Patients with Cardiovascular Disease'. Together they form a unique fingerprint.

Cite this